Breakthrough in Blood: Cécile Denis and INSERM Team Develop Nanobody Therapy for Type 1 VWD
Cécile Denis, director of research at INSERM, shared a post on LinkedIn:
”The result of an almost 10-year journey: a bispecific nanobody bridging von Willebrand factor to albumin in order to prolong the half-life of VWF and increasing its plasma levels. A potential treatment for patients with decreased VWF levels (Type 1 VWD).
We should not forget that Von Willebrand disease remains largely underestimated and therefore untreated, especially in type 1 patients.
Thank you Ivan Peyron, Caterina Casari, Geneviève McCluskey, Stéphanie Roullet, Vincent Licari, Emilie BOCQUET, Claire Auditeau, Melanie Daniel, sophie susen, Olivier Christophe, Peter Lenting, HITh lab Inserm, INSERM, ANR Agence nationale de la recherche.”
Read the full study here.
Title: A bispecific nanobody for the treatment of von Willebrand disease type 1
Authors: Ivan Peyron, Caterina Casari, Genevieve McCluskey, Stéphanie Roullet, Vincent N Licari, Emilie Bocquet, Claire Auditeau, Melanie Y Daniel, Sophie Susen, Olivier D. Christophe, Peter J Lenting, Cécile V. Denis
Stay updated with Hemostasis Today.
-
Dec 9, 2025, 04:47Grigoris Gerotziafas: 3 ASH 2025 Poster Awards for Our Team!
-
Dec 9, 2025, 04:36Nathan Connell on the 1st von Willebrand Factor/Factor VIII Relevance Academy
-
Dec 9, 2025, 04:22Ibtesam Alsufyani on RBC Exchange: A Life-Saving Apheresis Procedure
-
Dec 9, 2025, 04:02Susan Shea on Advancement of Precision Platelet Transfusion Medicine
-
Dec 9, 2025, 03:50Ravi C Dara Shares WHO’s Phase A guidance for PBM from ISBT
-
Dec 9, 2025, 03:39Low Platelets in Pregnancy: A Clinical Reality Check from Abdul Mannan
-
Dec 9, 2025, 03:26Michael Dunn Reflects on all ASH25 Represents for the Bleeding Disorders Community
-
Dec 9, 2025, 03:24Arun V J: Blood Loss Isn’t Always an Emergency and Blood Isn’t Always the Answer
-
Dec 8, 2025, 22:24ASH25 Day 3: Don’t Miss The Highlights